Abstract:Clustered regularly interspaced short palindromic repeats (CRISPR)/Cas-associated systems have recently emerged as a focal point for developing next-generation molecular diagnosis, particularly for nucleic acid detection. However, the detection of proteins is equally critical across diverse applications in biology, medicine, and the food industry, especially for diagnosing and prognosing diseases like cancer, Alzheimer and cardiovascular conditions. Despite recent efforts to adapt CRISPR/Cas systems for protein detection with immunoassays, these methods typically achieved sensitivity only in the femtomolar to picomolar range, underscoring the need for enhanced detection capabilities. To address this, we developed CRISPR-AMPED, an innovative CRISPR/Cas-based immunoassay enhanced by magnetic proximity extension and detection. This approach combines proximity extension assay (PEA) with magnetic beads that converts protein into DNA barcodes for quantification with effective washing steps to minimize non-specific binding and hybridization, therefore reducing background noise and increasing detection sensitivity. The resulting DNA barcodes are then detected through isothermal nucleic acid amplification testing (NAAT) using recombinase polymerase amplification (RPA) coupled with the CRISPR/Cas12a system, replacing the traditional PCR. This integration eliminates the need for thermocycling and bulky equipment, reduces amplification time, and provides simultaneous target and signal amplification, thereby significantly boosting detection sensitivity. CRISPR-AMPED achieves attomolar level sensitivity, surpassing ELISA by over three orders of magnitude and outperforming existing CRISPR/Cas-based detection systems. Additionally, our smartphone-based detection device demonstrates potential for point-of-care applications, and the digital format extends dynamic range and enhances quantitation precision. We believe CRISPR-AMPED represents a significant advancement in the field of protein detection.

Target-triggered Catalytic Hairpin Assembly Activation of CRISPR/Cas12a for Amplified Detection of Therapeutic Monoclonal Antibody

Universal CRISPR/Cas12a-associated aptasensor suitable for rapid detection of small proteins with a plate reader

Aptamer-Linked CRISPR/Cas12a-Based Immunoassay

Aptamer-based protein molecule detection via cyclic reverse transcription coupling with self-priming hairpin-triggered CRISPR-Cas12a system

Asymmetric CRISPR enabling cascade signal amplification for nucleic acid detection by competitive crRNA

Enhancement of trans-cleavage activity of Cas12a with engineered crRNA enables amplified nucleic acid detection

Recognition-Driven Remodeling of Dual-Split Aptamer Triggering in Situ Hybridization Chain Reaction for Activatable and Autonomous Identification of Cancer Cells

Multivalent Duplexed-Aptamer Networks Regulated a CRISPR-Cas12a System for Circulating Tumor Cell Detection.

CRISPR-Cas and catalytic hairpin assembly technology for target-initiated amplification detection of pancreatic cancer specific tsRNAs

Dual-site Responsive Module-Triggered CRISPR/Cas12a Switch with Enhanced Reaction Kinetics for Specific Detection of PSA

Amplification-Free Ratiometric Electrochemical Aptasensor for Point-of-Care Detection of Therapeutic Monoclonal Antibodies

Enhanced CRISPR/Cas-Based Immunoassay through Magnetic Proximity Extension and Detection

Controllable Assembly of a Quantum Dot-Based Aptasensor Guided by CRISPR/Cas12a for Direct Measurement of Circulating Tumor Cells in Human Blood.

Structure-Switching Aptamer Triggering Hybridization Chain Reaction on the Cell Surface for Activatable Theranostics

Hybridization Chain Reaction-Based Aptameric System for the Highly Selective and Sensitive Detection of Protein

A novel universal small-molecule detection platform based on antibody-controlled Cas12a switching

Applying CRISPR/Cas13 to Construct Exosomal PD-L1 Ultrasensitive Biosensors for Dynamic Monitoring of Tumor Progression in Immunotherapy

An RNA-based Catalytic Hairpin Assembly Circuit Coupled with CRISPR-Cas12a for One-Step Detection of Micrornas

Chimeric Hairpin DNA Aptamer-Based Biosensing Platform for One-Step Therapeutic Monitoring of Bevacizumab

An amplification strategy for detecting HER2 with a quasi-targeted proteomics approach coupled with aptamer-triggered hybridization chain reaction

An ultrasensitive hybridization chain reaction-amplified CRISPR-Cas12a aptasensor for extracellular vesicle surface protein quantification